Đang chuẩn bị liên kết để tải về tài liệu:
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2 - positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Esophagogastric adenocarcinoma (EGA) currently represents a main cause of cancer related death. Despite an intensified treatment for locally advanced or metastatic EGA with a doublet chemotherapy consisting of a platinum compound and a fluoropyrimidine in combination with trastuzumab for HER2-positive disease or in selected cases with docetaxel, survival remains poor. | Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2 - positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial AIO STO 0217

TÀI LIỆU LIÊN QUAN

Nivolumab plus ipilimumab versus nivolumab in individuals with treatmentnaive programmed death-ligand 1 positive metastatic soft tissue sarcomas: A multicentre retrospective study

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: The IMAGE study

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: A population-based cohort study in Ontario, Canada

PRISM protocol: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in firstline treatment of patients with advanced or metastatic renal cell carcinoma

A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: The IpiGlio trial protocol

Intracranial antitumor responses of nivolumab and ipilimumab: A pharmacodynamic and pharmacokinetic perspective, a scoping systematic review

Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: Case report and literature review

A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)

PRIME-HCC: Phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: A case report